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ABSTRACT
Eph tyrosine kinase receptors are frequently overexpressed and functional in 
many cancers, and they are attractive candidates for targeted therapy. Here, we 
analyzed the expression of Eph receptor A3, one of the most up-regulated factors 
in glioblastoma cells cultured under tumorsphere-forming conditions, together with 
EphA2 and EphB2 receptors. EphA3 was overexpressed in up to 60% of glioblastoma 
tumors tested, but not in normal brain. EphA3 was localized in scattered areas of 
the tumor, the invasive ring, and niches near tumor vessels. EphA3 co-localized with 
macrophage/leukocyte markers, suggesting EphA3 expression on tumor-infiltrating 
cells of bone marrow origin. We took advantage of the fact that ephrinA5 (eA5) is 
a ligand that binds EphA3, EphA2 and EphB2 receptors, and used it to construct a 
novel targeted anti-glioblastoma cytotoxin. The eA5-based cytotoxin potently and 
specifically killed glioblastoma cells with an IC50 of at least 10
-11 M. This and similar 
cytotoxins will simultaneously target different compartments of glioblastoma tumors 
while mitigating tumor heterogeneity.
INTRODUCTION
Glioblastoma (GBM) is the most common and most 
aggressive type of primary brain tumor; it has a dismal 
prognosis in adults [1] and despite extensive efforts, 
median survival for patients with GBM remains below 15 
months [2, 3]. Limiting factors in GBM treatment include 
tumor cell resistance to chemotherapy and radiation 
therapy, and apoptosis in general [4]. Newly identified 
glioma stem-like cells (GSCs) are suspected to exhibit 
particular resistance to chemotherapy and radiation 
therapy [5, 6]. Brain tumors are also more difficult for 
drugs to reach because of the blood-brain tumor barrier 
(BBTB) and blood-brain barrier (BBB) [7]. Convection-
enhanced delivery (CED) is one of the potentially 
most effective strategies to overcome these barriers by 
delivering the drug directly to tumor or around the tumor 
resection cavity [8, 9].
Molecular-targeted therapy aims at improving 
specific drug delivery to tumor cells and minimizing 
damage to healthy tissue [10]. Two promising 
pharmaceutically targetable biomarkers for GBM include 
interleukin-13 receptor α chain variant 2 (IL-13RA2) 
[11] and the Eph receptor A2 [12–15]; together, these 
are overexpressed in over 90% of GBMs [16]. Recently, 
the Eph receptor A3 has been recognized as a promising 
target in GBM. The role of EphA3 is to maintain the de-
differentiated state of tumor cells in the more aggressive 
mesenchymal subtype [17, 18]. EphA3 depletion or 
treatment with specific anti-EphA3 monoclonal antibody 
reduced cell tumorigenicity in vivo by targeting tumor-
initiating cells [17].
Both Eph receptors A3 and A2 belong to the EphA 
subfamily of receptor tyrosine kinases (RTKs) [19]. Eph 
receptors are the largest sub-family of RTKs, with 16 
known members. They are divided into “A” and “B” sub-
classes, and nearly all are activated by ephrin (Eph family 
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receptor interacting proteins) ligands that belong to the 
corresponding class [20, 21]. These receptors are activated 
upon binding with their cognate ephrin ligands, which 
induces receptor clustering followed by internalization 
and degradation (Supplementary Table S1) [20, 21]. Eph 
receptors and their corresponding ligands play critical 
functions during early embryogenesis and development 
[22], and in various pathologies, malignancies, and 
injuries in adults [23]. Eph receptors A3 and A2 have 
been related to several malignancies, including androgen-
independent prostate tumor [24], hepatocellular carcinoma 
[25], hematological cancers, and GBM [12, 15, 26]. We 
have previously documented that EphA2 as a targetable 
receptor in GBM [15, 27]. Of interest, a receptor from the 
B family of Ephs, EphB2, is overexpressed in GBM and 
correlates with reduced cellular proliferation and increased 
migration in vitro in a xenograft model of GBM [28, 29]. 
EphB2 was also suggested as a prognostic factor in human 
pancreatic cancer [30]. Hence, the Eph family of receptors 
plays an important role in oncological disorders.
Bacterial- and plant-based cytotoxins and 
immunotoxins have been employed in molecular-targeted 
therapies to specifically attack malignant cells overexpressing 
cell surface receptors [31–33]. Targeted toxins have already 
been used in GBM treatment, showing high potency in vitro 
and promising results in vivo when administered locally by 
CED [11, 34]. Bacterial toxins like Pseudomonas exotoxin 
A (PE) or Diphtheria toxin enter the cells by receptor-
mediated endocytosis and, following the endosomal pathway 
through the trans-Golgi and the endoplasmic reticulum, 
they translocate to the cytoplasm. There they block protein 
synthesis by ADP-ribosylation of elongation factor-2 (EF-2) 
thereby causing cell death [11, 32, 35].
In the present work, we document over-expression 
of the EphA3 receptor, in conjunction with over-
expression of the EphA2 and EphB2 receptors, in various 
compartments of GBM tumors. We also exploited 
ephrin-A5 (eA5) as a targeted ligand in the production 
of a conjugate cytotoxin, taking advantage of its ability 
to bind EphA2, EphA3, and EphB2 [36, 37]. Our data 
demonstrate that we can simultaneously target all three 
receptors over-expressed in GBM that localize to different 
tumor compartments, therefore potentially eliminating 
tumor-initiating and differentiated cells, neovasculature, 
infiltrating tumor cells and abnormal cells in the tumor 
microenvironment.
RESULTS
EphA3 is upregulated in GBM cells under 
tumorsphere-forming conditions
The Eph family of receptors shows promise for 
pharmaceutical development to find new targetable 
receptors in GBM [27, 38, 39]. In an effort to find new 
targetable receptors in GBM, including glioma stem-
like cells (GSCs), G48a GBM cells were grown under 
tumorsphere-forming conditions. Microarray data analysis 
showed that one of the most significantly up-regulated 
genes was EphA3, among other genes like Thsd7A, Msi2, 
Trpm8, and Gpm6A; the genes most down-regulated were 
Tk1, Fst, Anln, AnxA, and Stxbp6. Protein levels of EphA3 
also increased 2-3 fold compared to standard in-adherence 
growing G48a cells (Figure 1A). This difference in protein 
expression was much greater (19-fold) in non-passaged 
GBM cells obtained from the specimen BTCOE4843 
(Figure 1B). In addition, we observed co-staining of EphA3 
with one of the GSC marker Nestin in a GBM specimen 
in situ (Figure 1C). These results are consistent with a 
potential role for EphA3 in tumor-initiating cell populations 
and its largest presence in the mesenchymal subtype of 
GBM, which has been recently reported by others [17].
EphA3 is overexpressed in GBM specimens, but 
not normal brain
We next analyzed specimens of primary brain 
tumors for the presence of EphA3. The receptor was over-
expressed in 7 of 12 of GBM tumor lysates (58%) but 
not in normal brain (Figure 1D). Only two specimens 
of this group of GBMs contained EphA3, at very low 
levels (BTCOE4607 and 4764). The presence of eA5 
was variable and the ligand was over-expressed in 33% 
of tumors (Figure 1D). We screened more normal brain 
samples and found no to negligible expression of the 
receptor (Supplementary Figure S1A); only the specimen 
obtained from a trauma victim had more readily detected 
EphA3 (Supplementary Figure S1A, NB4656).
For comparative purposes and for assessing 
heterogeneity of the receptors over-expression, we 
analyzed GBM specimens for EphA3, EphA2 and EphB2 
receptors in the same tumors. The results for individual 
receptors were similar to the previously reported by us 
and others [15, 17, 28, 29]. Only one specimen of GBM, 
BTCOE4441, did not express appreciably any of the 
three receptors (Figure 1E). EphA3 was also present in 
all 4 anaplastic oligodendrogliomas examined (WHO 
grade II/III) and less so in meningiomas and lower grade 
astrocytomas (WHO grade II) (Supplementary Figure 
S1B). Therefore, targeting the three Eph receptors would 
cover vast majority of patients with GBM.
The presence of EphA3 was also examined by 
immunofluorescent staining of a brain of patient with 
GBM (G204; donated brain for research). EphA3 was 
largely present in scattered areas within the tumor and of 
the invading ring, but not in the contralateral side (Figure 
2A). To detect EphA3 on neuronal cells, we co-stained 
the sections with NeuN antibody. We observed no co-
staining of EphA3 with NeuN (Figure 2A). EphA3 and 
EphA2 localization was also analyzed in another human 
GBM specimen (Figure 2B). EphA3 was detected in the 
perivascular space, but it showed a limited co-staining 
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with EphA2 within the tumor area (Figure 2B). EphA2 
was found on endothelial cells of tumor neovasculature, 
as reported [15], and in the surrounding areas (Figure 2B). 
This was further emphasized by staining GBM specimens 
for EphA3 and CD31 (Figure 2C and Video 2C, and 
Figure 2SA-2SB). Moreover, EphA3 or EphA2 receptor 
could not be detected specifically in the hippocampal 
region of mouse brain (Figure 3A), in which an EphA3/
EphA2-positive tumor was grown (Figure 3B); Figure 
3C-3D represent respective controls. Thus, EphA3 is not 
detected in the areas of neuronal regeneration in the brain.
EphA3 and EphA2 are highly expressed in GBM 
cells
EphA3, EphA2, and eA5 and eA1 protein levels 
were studied by Western blot in several established 
human GBM cell lines. The receptors displayed similar, 
but not identical immunoreactive profiles, and were 
highly overexpressed in most cell lines tested compared to 
transformed SVGp12 glial cells (Figure 4A). Interestingly, 
the Eph receptors ligands eA5 and eA1 were absent or 
detected at much lower levels than in tissue specimens 
(Figure 4A).
EphA3 and EphA2 protein levels were also 
evaluated in low-passage GBM cell explant lines and 
compared to those in tumors they were derived from. 
The EphA3 receptor was over-expressed in around half 
of tumor specimens and in most of the isolated cell lines 
(Figure 4B). However, in a highly cystic GBM sample 
(BTCOE4843), EphA3 was present in a tumor lysate, but 
barely detectable in tumor-derived cells. These results 
suggested EphA3 over-expression in a population of cells 
in the tumor microenvironment that are not necessarily 
Figure 1: Immunoreactive profile of EphA3 in GBM tumorspheres and snap-frozen tumor specimens. A. Western blot 
analysis of EphA3 expression in a G48a GBM cell line grown under standard (left) or under tumorsphere-promoting culture conditions 
[46, 50]. B. Same as in A, but the GBM cells were never passaged and derived from the human specimen BTCOE4843. Nestin and GFAP 
imunoreactivity was also examined. C. Immunofluorescent staining of EphA3 (red) and Nestin [50] (green) in a BTCOE4443 human 
GBM specimen in situ. Nuclei are stained with DAPI (blue). D. Western blot analysis of EphA3 and eA5 expression in 12 GBM (grade IV 
astrocytoma) human specimens compared to normal human brain. E. Same as in D, but the GBM specimens were examined also for the 
presence of EphA2 and EphB2.
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Figure 2: Immunofluorescent staining of EphA3 in GBM. A. Immunofluorescent staining of EphA3 (red) and NeuN (green) 
within the tumor, invading and contralateral areas in a patient who died from GBM (specimen G204). B. Immunofluorescent staining of 
EphA3 (red) and EphA2 (green) in a BTCOE4443 human GBM specimen.
(Continued )
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Figure 3: Immunohistochemistry for EphA3 and EphA2 in a mouse brain carrying G48a tumors. The hippocampal area 
A. and tumor-normal brain margin B. were examined. The hippocampal area did not stain specifically for either the receptor, except for 
tumor-infiltrating cells (arrows). 
Figure 2 (Continued) C. Confocal immunofluorescent staining of EphA3 (red) and CD31 (green) in two GBM specimens using stacked 
2D images. Nuclei are stained with DAPI (blue).
(Continued )
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Figure 4: Eph receptor A3 is over-expressed in GBM cell lines and tumors. A. Western blot analyses of EphA3 and EphA2 and 
their ligands, eA5 and eA1, respectively, in brain tumor cell lines and in SVG p12 glial cells. B. Western blot analyses of EphA3 and EphA2 
in GBM primary cells compared to tumor specimens they were derived from. C. Flow cytometry for EphA3 and EphA2 in established 
GBM cell lines. U-251 MG (1) was performed using full antibody while U-251 MG (2) was performed using in-house made scFv fragment 
of anti-EphA3 antibody. D. The presence of immunoreactive EphA3 and EphA2 in membrane and cytosol/cytoskeleton fractions of U-251 
MG cells.
Figure 3 (Continued) C. and D. are the respective isotype-matched controls. MoDG, molecular layer dentate gyrus; GrDG, granular 
layer dentate gyrus; PoDG, polymorphic layer dentate gyrus; TC, infiltrating tumor cells.
Oncotarget59866www.impactjournals.com/oncotarget
transformed tumor cells. The tumors used in this particular 
experiment had lower levels of the EphA2 receptor 
initially, but the cells cultured from these tumors exhibited 
high expression of the receptor (Figure 4B). In this assay 
and others, immunoreactive bands corresponded to EphA3 
receptors of different mobilities on gels (e.g., Figure 1E 
and S1B). This suggests that the receptor might have a 
different post-translational status.
Next we treated lysates of GBM specimens 
(BTCOE4536 and 4637) with PNGaseF (Supplementary 
Figure S3A) and EndoH (Supplementary Figure S3B). 
Both enzymes caused a release of smaller molecular 
weight forms of immunoreactive EphA3, confirming that 
the receptor undergoes glycosylation (Supplementary 
Figure S3) Furthermore, EphA3 and EphA2 were 
detectable in U-251 MG, BTCOE4795, LN229, and T98G 
GBM cells by flow cytometry (Figure 4C); better detection 
of EphA3 was obtained with the use of single-chain Fv 
(U-251 (2)) than whole antibody (U-251 (1)). We further 
studied the presence of the receptors in different cellular 
compartments by separating membrane from cytosolic 
fraction of GBM cells. Both EphA3 and EphA2 were 
associated with membrane and cytosolic/cytoskeleton 
fractions (Figure 4D).
The results suggest that the expression of EphA3, 
EphA2, eA1, and eA5 in cells in culture differ from their 
expression in tumor specimens pointing to an elevated and 
more frequent expression of the receptors in cells than 
tumors and the opposite true for the ligands.
EphA3 co-stains with macrophage/leukocyte 
markers
Macrophages often localize along blood vessels, 
in the perivascular space in GBM (Figure 5A). Hence 
we further analyzed the expression and localization of 
EphA3 on consecutive sections of the GBM specimens 
BTCOE4443, BTCOE4843 and BTCOE4795. EphA3 
also showed a modest co-staining with glial fibrillary acidic 
protein (GFAP) (Figure 5B and Supplementary Figure 
S4A). We next examined EphA3 in relation to macrophages 
because these cells highly infiltrate gliomas, contributing to 
total tumor mass [40]. We stained the specimens for three 
markers of cells of monocyte/macrophage lineages: CD68, 
CD163, and CD206. Surprisingly, all three monocyte/
macrophage markers co-stained with EphA3 in a sub-
population of cells surrounding tumor vasculature and in 
the core of the tumor (Figure 5B and Supplementary Figure 
S4A). To further study the possibility of co-localization 
of EphA3 receptor and bone marrow-derived cells, we 
performed confocal microscopy. We found that CD68 
and EphA3 co-stain in a GBM tumor microenvironment 
indeed (Figure 5B and Supplementary Figure S4A; Figure 
5C and Video 5C, and Supplementary Figure S4B-S4C). 
In addition, we stained for a leukocyte marker CD45 and 
EphA3 by immunofluorescence (Figure 5D) and performed 
Z-stack confocal microscopy (Figure 5E-5F and Video 5E, 
and Supplementary Figure S4D. Similarly to macrophage 
markers, CD45 co-stained with EphA3 in a subgroup of 
cells. In further analysis of immune cells, we did not find 
any expression of the EphA3 receptor in the activated 
CD4+ T cells (Figure 5G).
EA5 conjugate to pseudomonas exotoxin A (eA5-
PE-C) potently kills GBM tumor cells
Having established that EphA3 and EphA2 
together are promising molecular targets in GBM 
tumor cells, tumor neovasculature (EphA2) [15], 
tumor-initiating [12, 17] and tumor-infiltrating cells of 
monocytic origin, we focused on combinatorial targeting 
of these receptors. The EphA3, EphA2, and EphB2 
receptors are recognized by eA5 [36] (Supplementary 
Table S1). We produced a recombinant dimeric form of 
eA5 in fusion with the Fc region of human IgG1 (eA5-
Fc) (Supplementary Figure S5A). The recombinant 
homodimer (created in our laboratory) showed the 
same mobility pattern as the products obtained from 
commercial sources like eA5-Fc and eB2-Fc on SDS-
PAGE (Supplementary Figure S5B). The commercial 
eA5-Fc may undergo some proteolytic degradation, 
unlike our constructs in which eA5 no longer has a 
proteolysis-sensitive site (Supplementary Figure S5B-
S5C) [41]. EA5-Fc was active in inducing EphA2 
receptor degradation in U-251 MG cells during 4 
hours of treatment, a phenomenon characteristic of the 
internalized Eph receptors [27] (Figure 6A). The dimeric 
ligand induced EphA3 degradation from 2 to 24 hours 
post-treatment; protein levels were completely restored 
at 48 hours compared to untreated cells. EphA2 showed 
pronounced degradation starting at 4 hours of treatment, 
and even at 48 hours, protein levels did not recover 
(Figure 6A). Moreover, in-house made eA5-Fc caused 
EphA3 to be phosphorylated at Y779 (Figure 6B) Thus, 
our eA5-Fc exhibits the expected biological activity. 
Subsequently, we produced a dimeric eA5-PE38QQR 
cytotoxin as a chemically conjugated form termed eA5-
PE-C (Figure 6C). The conjugated cytotoxin derived 
from eA5-Fc chemically linked to PE38QQR [42] 
produced several conjugates; most resulted in a 1:1 or 
a 1:2 stoichiometric ratio between ligands and toxins.
Initially, the two cytotoxins were tested in human 
brain normal microvascular endothelial cells (HBMEC), 
human dendritic cells, and U-251 MG tumor cells using 
MTS/PMS cell viability assays. We did not see any 
killing effect in normal HBMEC or dendritic cells after 
treatment with conjugated cytotoxin or a mixture of eA5-
Fc and PE38QQR (Figure 6D). Conversely, we observed 
a potent killing effect of eA5-PE-C in U-251 MG cells 
(Figure 6D). Assuming a 1:1 stoichiometric linkage 
between eA5-Fc and PE38QQR, the IC50 of the conjugate 
was in a range of 10−11 M. The mixture of eA5-Fc and 
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Figure 5: EphA3 co-stains with macrophage/leukocyte markers. A. Immunofluorescent staining of CD68, GFAP and Von 
Willebrand factor in a GBM specimen. B. Immunofluorescent staining of EphA3 (red) and CD31, GFAP, CD68, CD163, and CD206 on 
consecutive frozen sections of BTCOE4443 human GBM specimen. Nuclei are stained with DAPI (blue). Selected areas were magnified 
(last column on the right). 
(Continued )
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Figure 5 (Continued): C. Confocal immunofluorescent staining of EphA3 and CD68 in a GBM specimen using stacked 2D images. D, 
E.-stacked 2D images, and
(Continued )
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PE38QQR produced no effect in GBM cells (Figure 
6D). Even though the killing curves did not reach values 
near zero in a colorimetric cell viability assay based on 
enzymatic activity, in live/dead tests the vast majority of 
cells appeared to be dead at 10 ng/ml of conjugate, and 
almost all cells were dead at 1,000 ng/ml (Supplementary 
Figure S6).
We further analyzed the effect of eA5-PE-C 
conjugate in U-251 MG, U-373 MG, G48a and low 
passage BTCOE 4536 GBM cells (Figure 6E). As 
expected, the cytotoxin was very active in killing these 
GBM cells (Figure 6E). To confirm the specificity of the 
cytotoxin in targeting respective receptors, the GBM 
cells were pre-treated with either eA5-Fc or eA1-Fc. The 
treatment with eA5-Fc should block both EphA receptors, 
plus the EphB2 receptor [34]. EA1-Fc binds only EphA2; 
hence, EphA3 and EphB2 should remain available to the 
cytotoxin. As expected, the cytotoxin was significantly less 
active in the three cell lines tested when pre-treated with 
eA1-Fc, but lost activity when cells were pre-treated with 
eA5-Fc (Figure 6E). For the U-251 MG data, the group-
by-dose interaction was highly statistically significant 
(p<0.0001), suggesting that the differences between 
groups were dose-dependent. In addition, due to the highly 
consistent outcomes across replicates within each group 
at each dose, the 3 groups were statistically significantly 
Figure 5 (Continued): F. Confocal microscopy of co-staining of EphA3 and CD45 in GBM specimens. G. CD4+ T cells do not express 
the EphA3 receptor. Western blot analysis of peripheral blood mononuclear cells (PBMC), CD4+ and CD4+ activated T cells were probed 
for EphA3 immunoreactivity.
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Figure 6: EA5-Fc based anti-GBM cytotoxin. A. Western blot analysis of EphA3 and EphA2 degradation following treatment 
with 1 μg/mL of eA5-Fc in U-251 MG cells. B. eA5-Fc (made in-house) causes down-regulation (left panel) and phosphorylation at Y779 
(right panel) of the EphA3 receptor. C. SDS-PAGE of eA5-Fc, PE38QQR and the derived eA5-PE-C chemically conjugated cytotoxin. 
D. MTS/PMS cell viability assay on normal brain endothelial (HBMEC) and dendritic cells (DC), and U-251 MG GBM cells treated with 
eA5-PE-C cytotoxin or a mixture of eA5-Fc+ PE38QQR for 48 hrs. E. MTS/PMS cell viability assay in U-251 MG, U-373 MG, G48a and 
low passage BTCOE4536 GBM cells using eA5-PE-C and blocking with unconjugated eA1 and eA5 ligands. IC50s (ng/ml) are indicated 
in the individual panels. To analyze data, we used a 2-way analysis of variance (ANOVA) model with dose (5 levels) and group (3 levels) 
as factors (see methods).
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different from each other at each dose (p-values from 
<0.001 – 0.0039) with the ea5-Fc having highest percent 
values, eA1-Fc having intermediate values, and eA5-
PE-C having the lowest values. For the U-373 MG data, 
the group-by-dose interaction was highly statistically 
significant (p=0.0014), suggesting that the differences 
between groups were dose-dependent. The overall test for 
differences among the 3 groups was significant (p<0.001) 
at the 1, 10, 100, and 1,000 ng/ml dose levels. Similar 
results were obtained for G48a cells.
DISCUSSION
In the present study, we provide supportive evidence 
that the EphA3 receptor is an attractive molecular target 
for GBM. EphA3 was over-expressed in most GBM 
specimens tested. It also was present in tumor cells, 
including the invading ring of the tumor, but not in normal 
brain, including the areas known to contain progenitor 
cells of the central nervous system. In addition, EphA3 is 
present in GBM tumor-initiating cells, with a prominent 
effect on their biological behavior, as demonstrated by 
others [17]. Here, we also demonstrate that the EphA3 
receptor is expressed in GBM tumor-infiltrating cells of 
bone marrow origin, macrophage/leukocyte cells, which 
have been implicated in GBM progression [27]. The 
distribution of EphA3 and EphA2, a receptor that we had 
previously found in GBM [15], differs. Therefore, it would 
be advantageous to target these receptors together in a 
combinatorial approach. The eA5 ligand can potentially 
fulfill such a role; thus, we generated an eA5-based 
chimeric cytotoxin, linking the eA5-Fc dimeric ligand to 
a truncated form of PE [42]. The cytotoxin was effective 
in targeting GBM tumor cells, triggering potent tumor cell 
killing.
The Eph family of receptors is amenable to the 
development of targeted therapies [27, 38]. GSCs are 
a small population of slow-dividing and self-renewing 
glioma cells characterized by an increased resistance to 
chemotherapy and radiotherapy [5]. Because of their role 
in sustaining tumor growth, it is of great interest to find 
new molecular markers that will specifically target GSCs. 
The Eph receptor A3 was upregulated in tumorspheres of 
established G48a GBM cells and also in never-passaged 
GBM explant cells. Not only were EphA3 protein levels 
increased in tumorspheres, we also observed a high 
degree of co-staining with the cancer stem cell marker 
Nestin in situ. These data together support an important 
role of EphA3 in tumor-initiating cells, as previously 
proposed [17]. We have previously shown that a soluble 
form of eA1 ligand is still active in inducing EphA2 
down-regulation and thus in reducing the oncogenic 
potential of GBM tumor cells [43]. Similarly, GBM cells 
overexpressing EphA3 and treated with a monoclonal 
antibody to deplete the receptor showed markedly 
reduced tumorigenicity [17].
The tumor microenvironment is a complex mixture 
of cells that surround and support tumor cells; this mixture 
can influence tumor progression and therapeutic response/
resistance of the treated lesion [26, 44]. Macrophages 
highly infiltrate gliomas, favoring glioma growth [40]. 
Interestingly EphA3 was identified as one of the RTK-
specific transcripts in bone marrow mesenchymal stromal 
cells (BMMSCs) [45] and the receptor is overexpressed 
primarily in the mesenchymal GBM genomic subtype 
[17]. Taken together, these results suggested a possible role 
of EphA3 in tumor-infiltrating macrophages/leukocytes. 
We found that EphA3 co-stains with cells markers of the 
macrophage/leukocyte lineages CD68, CD163, CD206, 
and CD45. In addition, recent findings localized EphA3 
predominantly to the stromal tumor microenvironment 
of lung, prostate, and colon cancers, and mouse tumor 
xenografts [46].
EphA3 is thus present on tumor cells, tumor-
initiating cells, infiltrating tumor cells, and tumor-
infiltrating cells of monocytic origin. EphA2 is 
overexpressed in tumor cells, tumor-initiating cells, and 
in tumor neovasculature. Eph receptors A2 and A3, as 
well as EphB2, share the property of being activated upon 
binding with the same ephrin ligand, eA5 [36, 51]. Of 
importance, eA5 is expressed in gliomas and has a strong 
tumor suppressing activity in gliomas [52]. We exploited 
these features to design a novel eA5-based cytotoxin to 
target GBM cells over-expressing the three receptors. The 
chimeric cytotoxin was generated by linking eA5-Fc to 
PE38QQR. The novel eA5-based cytotoxin was neutral 
to normal cells tested, but effectively killed tumor cells 
demonstrating overexpression of EphA3, EphA2, and 
EphB2 receptors.
In summary, similarly to another group, we 
found EphA3 to be an attractive target in GBM. We 
produced a highly potent eA5-based cytotoxin that kills 
tumor cells over-expressing receptors EphA3, EphA2, 
and also EphB2. These receptors together localize to 
subpopulations of cells related to tumor progression, 
invasion, recurrence, and resistance to therapies. EphA2 
was previously found in infiltrative [15] and tumor-
initiating cells [12] and EphA3 is also overexpressed 
in the invading ring of the tumor. The possibility of 
specific killing of residual tumor cells by delivering 
the cytotoxin locally and safely is of great interest as a 
new therapeutic option in GBM treatment. Moreover, 
the eA5-based cytotoxin simultaneously targets several 
Eph receptors at a time that are overexpressed in various 
compartments of GBM tumors, but not normal brain. This 
should allow more comprehensive molecular targeting in 
this disease, because GBM tumor heterogeneity will be 
addressed at two levels: 1) different tumor compartments, 
and 2) differing levels of targeted receptors’ expression 
among different tumor compartments. In addition, the 
cells evading killing by the eA5-based cytotoxin due to 
insufficient amount of the targeted receptor expression 
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will be bound by a tumor suppressor, which represents an 
exceptionally attractive therapeutic scenario. In translation 
to the clinic, it is envisioned that the cytotoxin will be 
tested pre-clinically in a canine model of glioma [53] and 
then administered first to patients with recurrent GBM 
using advanced reflux-preventing catheters [8] with real-
time monitoring of drug’s distribution [54].
MATERIALS AND METHODS
Cell lines, tissues and reagents
U-251 MG, U-373 MG A-172 MG, U-87 MG, 
SNB19, DBTRG-50 MG, LN229, and T98G cell 
lines were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA) and grown in their 
recommended media. HBMEC cells were a kind gift of Dr. 
L. J. Metheny-Barlow and were cultured in the supplier-
recommended media. G48a cells were isolated in our 
laboratory from a human primary high-grade astrocytoma 
[47]. All human samples were handled according to Wake 
Forest IRB-approved protocol (#8427).
Early-passage tumor cells were derived from human 
GBM tumors obtained from the operating room and 
processed within 20 minutes of resection. Tumors were 
minced into small pieces and digested with Collagenase II, 
Collagenase IV, and DNAse (Sigma) for 30 minutes at 37 
°C. The cell suspension was layered over a ficoll gradient 
and centrifuged at 300xg for 35 min. The interface was 
washed twice with phosphate-buffered saline (PBS) 
and the cells cultured in RPMI-1640 containing 10% 
fetal bovine serum (FBS) and 4g/L glucose. U-251 MG, 
U-87 MG, and A-172 MG cells have been authenticated 
and BTCOE4525, BTCOE4795, and BTCOE4536 cells 
were validated to the original tumor by Idexx Radil 
(Columbia, MO). No information regulated by the US 
Health Insurance Portability and Accountability Act was 
included in the study, which qualified for exemption #4 of 
the National Institutes of Health.
EphA3 and EphA2 down-regulation assays
EphA2 and EphA3 down-regulation assays were 
performed as previously described [48].
Recombinant proteins design, expression and 
purification
The EA5 gene was synthesized based on the 
GeneBank database (NCBI) sequence AAH75054.1 
and cloned into BamHI-EcoRI sites in the modified 
Baculovirus transfer vector pAcGP67-B (BD Biosciences, 
San Diego, CA) [48, 49]. Recombinant truncated eA5 
(aa. 21-191) [41] was produced in the dimeric form (C-
terminal Fc tag) in the Baculovirus expression system (BD 
Biosciences) as previously described [48, 49]. PE38QQR 
was produced and purified in our laboratory as previously 
described [42].
Chemical conjugation and cell viability assays
Protein conjugation was achieved following a 
previously reported protocol [35] combining eA5-
Fc to PE38QQR in a 1:3 molar ratio. The conjugated 
cytotoxin was additionally purified by size exclusion 
chromatography. Cell viability assays were performed 
using the CellTiter 96® AQueous Non-Radioactive Cell 
Proliferation Assay (MTS) following the instructions of 
the manufacturer (Promega, Madison, WI).
EphA3 scFv-Fc production for flow cytometry
Vκ and Vh sequences derived from humanized 
EphA3 antibody (clone IIIA4) (patent application 
US20140120114 A1) were synthesized with a glycine-
serine linker and inserted in-frame with a honeybee 
secretion signal and a human IgG1 Fc cloned in our 
laboratory. This construct was transfected into Sf9 cells 
and the protein was collected from the media. Following 
purification on a protein G column, the protein was 
concentrated and filter sterilize. 2 μg/100 μl was used for 
flow cytometry followed by detection with anti-human 
Alexa-488.
Western blots
Cell lysates were prepared by lysing cells in RIPA 
buffer with proteases and phosphatases inhibitors (Sigma), 
and separated by 10% SDS-PAGE. Western blotting 
was performed as previously described [15]. Primary 
antibodies from Santa Cruz Biotechnology (Santa Cruz, 
CA) included: EphA3 (C-19), EphA3 (L-18), ephrin-A5 
(RR-7), and ephrinA1 (V-18). Other antibodies used were 
EphA2 (clone D7) (EMD Millipore Corporation, Billerica, 
MA) and β-actin (Sigma).
Immunofluorescent staining
Immunofluorescent staining was performed as 
described previously [15]. Primary antibodies used 
include: EphA3 C19 (Santa Cruz), EphA2 clone D7 
(Millipore, Billerica, MA), NeuN clone A60 (Millipore), 
GFAP (Santa Cruz), CD31 (Pierce, Rockford, IL), CD68 
clone SPM281 (Novus Biologicals, Littleton, CO), CD163 
clone 5C6FAT (Novus Biologicals), Nestin (1:200, Santa 
Cruz) and CD206 clone 15-2 (Santa Cruz).
Immunohistochemistry
5x105 G48a GBM cells were injected intracranially 
into brains of nu/nu mice 2 mm to the right and 3 mm 
rostral to Bregma at a depth of 1 mm. Tumors were 
allowed to develop for 6 weeks at which time mice 
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were euthanized. Mouse brains were fixed in 10% 
formalin and embedded in paraffin. Sections were cut 
at a thickness of 8 μm. Slides were heated at 65 °C, 
de-paraffinized in xylene, and rehydrated. The staining 
was performed according to our standard protocol. The 
experiment was performed under Wake Forest IACUC 
protocol A-14-223.
Flow cytometry
Cells were detached with EDTA, washed, and 
resuspended in 100 μl PBS containing 1% bovine serum 
albumin (BSA). 2x105 cells were blocked with PBS/1% 
BSA for 1 hour on ice. 2 μg of EphA3 antibody L-18 
(Santa Cruz Biotech) or EphA2 clone B2D6 (Millipore) 
was added and incubated for 2 hours on ice with occasional 
mixing. Cells incubated with isotype antibody served as 
controls. Cells were washed 3 times with PBS/1% BSA 
by centrifugation and resuspended in 100 μl PBS/BSA. 
2 μg anti-mouse or anti-human Alexa 488 secondary 
antibody was added and cells were incubated on ice for 
an additional 1 hour with occasional mixing. Cells were 
washed 3 times with PBS/1% BSA by centrifugation and 
resuspended in 500 μl PBS/BSA. 500 μl of 10% buffered 
formalin was added to post-fix cells. After washing with 
PBS/BSA, the cells were analyzed on an Accuri 6 flow 
cytometer. Data was analyzed using Flowing Software 
(Turko, Finland).
Confocal microscopy
Tissue sections were viewed and 0.5 μm z-stacks 
were acquired with an Olympus Fluoview 1200 confocal 
microscope (Cellular Imaging Core, Comprehensive 
Cancer Center of Wake Forest University). Stacked 
2D images were obtained in some cases. Images were 
processed with OlyVIA V2.8.
Dendritic cells
Myeloid-derived naïve dendritic cells were 
purchased from AllCells LLC (Alameda, CA). Cells were 
grown in RPMI-1640 containing 10% FBS, 20 ng/ml 
GM-CSF (PeproTech, Rocky Hill, NJ) and 20 ng/ml IL-4 
(made in our laboratory). Dendritic cells were matured by 
adding 20 ng/ml TNFα for 72 hours.
Isolation and activation of CD4+ T cells
Total CD4+ T Cells were isolated from PBMC 
(ZenBio, Durham, NC) using the Dynabeads Untouched 
human CD4+ T-Cell Kit (Invitrogen) according to the 
manufacturer’s instructions. The cells were plates at a 
density of 4 x 104/ml in RPMI-1640 containing 10% FBS, 
0.05 mM 2-mercaptoethanol and 30U/ml IL-2 (Peprotech, 
Rocky Hill, NJ). Cells were activated with CD3/Cd28 
magnetic beads (Invitrogen) for 3 days prior to preparation 
of lysates.
Tumorsphere preparation
Freshly dissected GBM tumors were digested with 
collagenase and DNAse. Cells were separated by layering 
over a Ficoll gradient and centrifuged at 300 xg for 35 
min. The interface was collected and washed twice with 
PBS. Control cells were plated on standard 6-cm dishes 
for 14 days in RMPI-1640 containing 10% FBS and 
adjusted to contain 4 g/L glucose. For tumorspheres, cells 
were plated on HydroCell 6-cm dishes (Thermo Scientific) 
in serum-free neurobasal media containing B27, N2, 
(Life Technologies), 20 ng/ml FGF, and 20 ng/ml EGF 
(PeproTech) for 14 days. Media in all dishes was refreshed 
every 2-3 days.
Membrane and cytosolic protein isolation
Membrane and cytosolic proteins from U-251 MG 
cells were obtained from 100-cm dishes at 90% confluence 
with ProteoJET Membrane Protein Extraction Kit 
(ThermoFisher Scientific) according to the manufacturer’s 
instruction.
Statistical analysis
To analyze data, we used a 2-way analysis of 
variance (ANOVA) model with dose (5 levels) and 
group (3 levels) as factors. We first examined whether 
there was a dose-by-treatment interaction to determine 
whether changes in outcome differed across the groups 
over the dose range. If this interaction was significant, 
then we fit 1-way ANOVA models at each dose to 
determine whether the 3 groups differed at a particular 
dose. If the overall 1-way ANOVA had a significant 
group effect, then we examined the 3 pairwise 
comparisons between groups within the ANOVA model 
using an Bonferroni adjusted p-value of 0.0167 to 
declare a pairwise comparison statistically significant to 
adjust for the multiple comparisons made at each dose 
(p=0.05/3 = 0.0167), at which dose the three groups 
separated from each other. All analyses were performed 
using SAS Version 9.3.
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